Bortezomib

Form: Injection (lyophilized powder for solution)

Strength: 1 mg/vial, 3.5 mg/vial

Reference Brands: Velcade® (US & EU)

Category: Oncology Cancer Care

Bortezomib Injection, available in 1 mg and 3.5 mg lyophilized vials, is a leading oncology drug used for multiple myeloma and mantle cell lymphoma in the EU and US markets. As a proteasome inhibitor, Bortezomib disrupts protein degradation in cancer cells, inducing apoptosis and inhibiting tumor growth. Marketed under the brand Velcade®, this essential anticancer agent is available for IV and subcutaneous use. GMP-compliant manufacturers supply Bortezomib as a sterile injectable formulation, making it a high-demand product for pharmaceutical B2B sourcing, licensing, and global distribution in regulated markets.